Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.
Chamberlain C, Colman PJ, Ranger AM, Burkly LC, Johnston GI, Otoul C, Stach C, Zamacona M, Dörner T, Urowitz M, Hiepe F. Chamberlain C, et al. Among authors: johnston gi. Ann Rheum Dis. 2017 Nov;76(11):1837-1844. doi: 10.1136/annrheumdis-2017-211388. Epub 2017 Aug 5. Ann Rheum Dis. 2017. PMID: 28780512 Clinical Trial.
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
Juarez M, Diaz N, Johnston GI, Nayar S, Payne A, Helmer E, Cain D, Williams P, Devauchelle-Pensec V, Fisher BA, Giacomelli R, Gottenberg JE, Guggino G, Kvarnström M, Mariette X, Ng WF, Rosas J, Sánchez Bursón J, Triolo G, Barone F, Bowman SJ. Juarez M, et al. Among authors: johnston gi. Rheumatology (Oxford). 2021 Mar 2;60(3):1364-1375. doi: 10.1093/rheumatology/keaa410. Rheumatology (Oxford). 2021. PMID: 32949140 Clinical Trial.
Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
Diaz N, Juarez M, Cancrini C, Heeg M, Soler-Palacín P, Payne A, Johnston GI, Helmer E, Cain D, Mann J, Yuill D, Conti F, Di Cesare S, Ehl S, Garcia-Prat M, Maccari ME, Martín-Nalda A, Martínez-Gallo M, Moshous D, Santilli V, Semeraro M, Simonetti A, Suarez F, Cavazzana M, Kracker S. Diaz N, et al. Among authors: johnston gi. J Immunol. 2020 Dec 1;205(11):2979-2987. doi: 10.4049/jimmunol.2000326. Epub 2020 Oct 28. J Immunol. 2020. PMID: 33115853 Clinical Trial.
Prevalence and markers of advanced liver disease in type 2 diabetes.
Williamson RM, Price JF, Hayes PC, Glancy S, Frier BM, Johnston GI, Reynolds RM, Strachan MW; Edinburgh Type 2 Diabetes Study Investigators. Williamson RM, et al. Among authors: johnston gi. QJM. 2012 May;105(5):425-32. doi: 10.1093/qjmed/hcr233. Epub 2011 Dec 7. QJM. 2012. PMID: 22156706
Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.
Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, Strachan MW; Edinburgh Type 2 Diabetes Study Investigators. Williamson RM, et al. Among authors: johnston gi. Diabetes Care. 2011 May;34(5):1139-44. doi: 10.2337/dc10-2229. Epub 2011 Apr 8. Diabetes Care. 2011. PMID: 21478462 Free PMC article.
The use of ultrasound to diagnose hepatic steatosis in type 2 diabetes: intra- and interobserver variability and comparison with magnetic resonance spectroscopy.
Williamson RM, Perry E, Glancy S, Marshall I, Gray C, Nee LD, Hayes PC, Forbes S, Frier BM, Johnston GI, Lee AJ, Reynolds RM, Price JF, Strachan MW; Edinburgh Type 2 Diabetes Study investigators. Williamson RM, et al. Among authors: johnston gi. Clin Radiol. 2011 May;66(5):434-9. doi: 10.1016/j.crad.2010.09.021. Epub 2011 Feb 22. Clin Radiol. 2011. PMID: 21345425
37 results